The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL

Cell Death and Disease

Volumn 8, Issue 7, 2017, Pages

  Delbridge, Alex R D ^a,b,c   Aubrey, Brandon J ^a,b   Hyland, Craig ^a   Bernardini, Jonathan P ^a,b   Di Rago, Ladina ^a   Garnier, Jean Marc ^a   Lessene, Guillaume ^a,b   Strasser, Andreas ^a,b   Alexander, Warren S ^a,b   Grabow, Stephanie ^a,b,d  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BIOGEN   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; PROTEIN BCL XL; PUMA PROTEIN; TAMOXIFEN; A-1331852; APOPTOSIS REGULATORY PROTEIN; BCL2L1 PROTEIN, HUMAN; BCL2L11 PROTEIN, MOUSE; BENZOTHIAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; PROTEIN BCL X; PUMA PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ANEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROCYTE COUNT; ERYTHROID CELL; ERYTHROPOIESIS; GENE DELETION; GENE LOSS; HEMATOCRIT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE; SPLEEN WEIGHT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ANEMIA; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; BCL-X PROTEIN; BENZOTHIAZOLES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ERYTHROBLASTS; ERYTHROPOIESIS; GENE DELETION; GENE EXPRESSION REGULATION; HUMANS; ISOQUINOLINES; MICE; MICE, KNOCKOUT; ORGAN SPECIFICITY; PROTEIN DOMAINS; RETICULOCYTES; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR SUPPRESSOR PROTEINS;

EID: 85022175877     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.304     Document Type: Article

References (49)

1. de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993-2005L WHO global database on anaemia. World Health Organisation: Geneva, Switzerland, 2008.
2. Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
3. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311-322.
4. Koury MJ. Tracking erythroid progenitor cells in times of need and times of plenty. Exp Hematol 2016; 44: 653-663.
5. Barminko J, Reinholt B, Baron MH. Development and differentiation of the erythroid lineage in mammals. Dev Comp Immunol 2016; 58: 18-29.
6. Magnani M, Rossi L, Stocchi V, Cucchiarini L, Piacentini G, Fornaini G. Effect of age on some properties of mice erythrocytes. Mech Ageing Dev 1988; 42: 37-47.
7. Dholakia U, Bandyopadhyay S, Hod EA, Prestia KA. Determination of RBC Survival in C57BL/6 and C57BL/6-Tg(UBC-GFP) Mice. Comp Med 2015; 65: 196-201.
8. L and apopain in the control of erythropoiesis by erythropoietin. Blood 1997; 90: 630-640.
9. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353: 1135-1146.
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
11. Horos R, von Lindern M. Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia. Br J Haematol 2012; 159: 514-527.
12. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
13. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
14. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682.
15. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
16. Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015; 22: 1071-1080.
17. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
18. O'Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev 2016; 30: 973-988.
19. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157-164.
20. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738.
21. Mason KD, Lin A, Robb L, Josefsson EC, Henley KJ, Gray DH et al. Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proc Natl Acad Sci USA 2013; 110: 2599-2604.
22. Delbridge AR, Opferman JT, Grabow S, Strasser A. Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. Blood 2015; 125: 3273-3280.
23. Opferman J, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of antiapoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-1104.
24. Motoyama N, Wang FP, Roth KA, Sawa H, Nakayama K, Nakayama K et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 1995; 267: 1506-1510.
25. Akhtar RS, Klocke BJ, Strasser A, Roth KA. Loss of BH3-only protein Bim inhibits apoptosis of hemopoietic cells in the fetal liver and male germ cells but not neuronal cells in bcl-x-deficient mice. J Histochem Cytochem 2008; 56: 921-927.
26. Wagner KU, Claudio E, Rucker EB 3rd, Riedlinger G, Broussard C, Schwartzberg PL et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127: 4949-4958.
27. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
28. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
29. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
30. Motoyama N, Kimura T, Takahashi T, Watanabe T, Nakano T. bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 1999; 189: 1691-1698.
31. Rhodes MM, Kopsombut P, Bondurant MC, Price JO, Koury MJ. Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. Blood 2005; 106: 1857-1863.
32. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
33. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943-951.
34. Delbridge AR, Chappaz S, Ritchie ME, Kile BT, Strasser A, Grabow S. Loss of PUMA (BBC3) does not prevent thrombocytopenia caused by the loss of BCL-XL (BCL2L1). Br J Haematol 2016; 174: 962-969.
35. Kodama T, Hikita H, Kawaguchi T, Shigekawa M, Shimizu S, Hayashi Y et al. Mcl-1 and BclxL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ 2012; 19: 1856-1869.
36. Liu J, Zhang J, Ginzburg Y, Li H, Xue F, De Franceschi L et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood 2013; 121: e43-e49.
37. Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res 2003; 31: e12.
38. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7: 279ra240.
39. Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci USA 2007; 104: 19500-19505.
40. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000; 275: 1439-1448.
41. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23: 33-42.
42. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
43. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-328.
44. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. BH3-only proteins Puma and Bim are rate-limiting for {gamma} -radiation and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138.
45. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010; 9: 229.
46. Yu H, Shen H, Yuan Y, Xufeng R, Hu X, Garrison SP et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose {gamma}-irradiation. Blood 2010; 115: 3472-3480.
47. Schaefer BC, Schaefer ML, Kappler JW, Marrack P, Kedl RM. Observation of antigendependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol 2001; 214: 110-122.
48. L expression. Blood 1999; 94: 87-96.
49. Caserta T, Smith A, Gultice A, Reedy M, Brown T. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003; 8: 345-352.